Tech Company Financing Transactions
Amicus Therapeutics Funding Round
Amicus Therapeutics, operating out of Cranbury, secured $55 million from Quaker Partners, Canaan Partners and CHL Medical Partners.
Transaction Overview
Company Name
Announced On
9/8/2005
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series C
Investors
Proceeds Purpose
The new funds will accelerate development of unique pharmacological chaperones to correct misfolded proteins.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Cedar Brook Dr.
Cranbury, NJ 08512
USA
Cranbury, NJ 08512
USA
Phone
Website
Email Address
Overview
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases. The Company has a robust development pipeline of treatments for a range of human genetic diseases.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 9/8/2005: MetaCarta venture capital transaction
Next: 9/8/2005: Cardiovascular Systems venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs